Register Login

EAGLE PHARMS INC (EGRX)

  • Event
  • June 01, 2022, 11:00 UTC

(10% Negative) Eagle Pharmaceuticals, Inc. (EGRX) Announces Delay in agreement Trials for our company Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 1, 2025, 11:01 p.m.

    📋 Eagle Pharmaceuticals, Inc. (EGRX) - Clinical Trial Update

    Filing Date: 2022-06-01

    Accepted: 2022-06-01 07:00:46

    Event Type: Clinical Trial Update

    Event Details:

    EAGLE PHARMS INC (EGRX) Announces Clinical Trial Update EAGLE PHARMS INC (EGRX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: agreement, footprint
    • Diseases/Conditions: our company, filing
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: Eagle Pharmaceuticals, Inc.
    • Updated Timeline: mid-year 2023

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: EAGLE PHARMS INC
    • CIK: 0000827871
    • Ticker Symbol: EGRX
    • Period End Date: 2022-06-01
    • Document Type: 8-K

Search

News categories